| Q42035380 | A 24-Week Treatment of Pediatric Hemangioma with Oral Propranolol |
| Q57820559 | A Newborn with Gastric Hemangioma Treated Using Propranolol |
| Q48194413 | Accurate p-values for adaptive designs with binary endpoints |
| Q59336746 | Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency |
| Q41116786 | Adult neck hemangiolymphangioma: a case and review of its etiology, diagnosis and management |
| Q39254396 | Advances in pharmacotherapeutic management of common skin diseases in neonates and infants |
| Q45292536 | An objective re-evaluation of adaptive sample size re-estimation: commentary on 'Twenty-five years of confirmatory adaptive designs'. |
| Q39027849 | Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. |
| Q61810181 | Association of Somatic GNAQ Mutation With Capillary Malformations in a Case of Choroidal Hemangioma |
| Q47726090 | Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study |
| Q92136235 | Beta Blockers in the Treatment of Periocular Infantile Hemangiomas: A Review |
| Q41667468 | Beta-adrenergic receptors are expressed across diverse cancers |
| Q24187442 | Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants |
| Q52677056 | Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants. |
| Q57813960 | Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta |
| Q40517442 | Blood Pressure Monitoring During the Induction and Maintenance Period of Propranolol Therapy for Complicated Infantile Hemangiomas: A Prospective Study of 109 Infants |
| Q45739121 | Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report |
| Q88801642 | Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants |
| Q26769978 | Cardiovascular drugs in the treatment of infantile hemangioma |
| Q61805151 | Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier |
| Q64111993 | Central Nervous System Effects of Oral Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis |
| Q36195375 | Clinical Characteristics and Treatment Options of Infantile Vascular Anomalies |
| Q41294103 | Clinician's Update on the Benign, Premalignant, and Malignant Skin Tumours of the Vulva: The Dermatologist's View. |
| Q38377887 | Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial |
| Q48174382 | Consensus statement for the treatment of infantile haemangiomas with propranolol |
| Q90484644 | Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting |
| Q93273515 | Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions |
| Q49932201 | Das infantile Hämangiom: Pathogenese und Wirkmechanismus von Propranolol |
| Q33802563 | Developing a Nanoparticle-Delivered High-Efficacy Treatment for Infantile Hemangiomas Using a Mouse Hemangioendothelioma Model |
| Q41002973 | Drug repositioning in sarcomas and other rare tumors |
| Q92035885 | EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT |
| Q38769283 | Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study |
| Q35777099 | Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis |
| Q47880456 | Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas |
| Q53500320 | Efficacy and safety of oral propranolol for infantile hemangioma in Japan. |
| Q89495715 | Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma |
| Q50195737 | Endoscopic Management of Developmental Anomalies of the Skull Base |
| Q49787990 | Endothelial Cell Metabolism. |
| Q92674148 | Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work |
| Q90580555 | Eyelid Thread-lifting Treatment for Periocular Infantile Hemangioma in an Extremely Premature Low-birth-weight Infant |
| Q95656631 | From real-world patient data to individualized treatment effects using machine learning: Current and future methods to address underlying challenges |
| Q64078523 | Genetic investigation of childhood vascular tumor biology reveals pathways for therapeutic intervention |
| Q38694569 | Incidence, Treatment Patterns, and Health Care Costs of Infantile Hemangioma: Results of a Retrospective German Database Analysis. |
| Q91866328 | Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study |
| Q38789878 | Infant Colic |
| Q55394881 | Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. |
| Q42022173 | Infantile Hepatic Hemangioendothelioma: An Uncommon Cause of Persistent Pulmonary Hypertension in a Newborn Infant |
| Q47871326 | Infantile Periocular Haemangioma: Optimising the Therapeutic Response |
| Q39089425 | Infantile haemangioma |
| Q49939553 | Infantile hemangioma of the eyelid |
| Q38393811 | Infantile hemangioma status by dynamic infrared thermography: A preliminary study |
| Q50092811 | Infantile hemangioma: factors causing recurrence after propranolol treatment |
| Q47386049 | Infantile hemangioma: pathogenesis and mechanisms of action of propranolol |
| Q46844431 | Infantile hemangiomas with conjunctival involvement: An underreported occurrence. |
| Q90700101 | Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma |
| Q53280418 | Interventions for infantile haemangiomas of the skin. |
| Q90570507 | Japanese Clinical Practice Guidelines for Vascular Anomalies 2017 |
| Q90581434 | Japanese clinical practice guidelines for vascular anomalies 2017 |
| Q90615462 | Japanese clinical practice guidelines for vascular anomalies 2017 |
| Q91988159 | Management of Infantile Hemangiomas during the COVID Pandemic |
| Q64970167 | Medical Management of Vascular Anomalies. |
| Q88561640 | Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution |
| Q33433230 | Multifocal infantile haemangioma: a diagnostic challenge |
| Q36211734 | Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children |
| Q38772074 | Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function |
| Q89792747 | On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients |
| Q89124970 | Oral Propranolol in a Child With Infantile Hemangioma of the Urethra |
| Q37205732 | Oral atenolol therapy for proliferating infantile hemangioma: A prospective study |
| Q36512006 | Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study |
| Q47594818 | Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment |
| Q90390691 | Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis |
| Q59800278 | Oral propranolol therapy in 23 infants with infantile hemangioma |
| Q48088481 | Orientation of the Mitotic Spindle in the Development of Tubular Organs |
| Q91825803 | Outcomes of surgical treatment for hemangiomas |
| Q38607717 | PHACE syndrome--clinical features, aetiology and management. |
| Q39177052 | Perianal Lesions in Children: An Updated Review |
| Q47217213 | Perioperative events influence cancer recurrence risk after surgery. |
| Q36117648 | Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies |
| Q49012688 | Phytochemical Inhibition of Multidrug Resistance Protein-1 as a Therapeutic Strategy for Hemangioendothelioma |
| Q54003242 | Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma. |
| Q33767409 | Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study |
| Q92593924 | Progress in the treatment of infantile hemangioma |
| Q34489319 | Propranolol Decreases Proliferation of Endothelial Cells Transformed by Kaposi's Sarcoma-Associated Herpesvirus and Induces Lytic Viral Gene Expression |
| Q36440738 | Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation |
| Q92312921 | Propranolol Treatment for Infantile Hemangiomas: Short-Term Adverse Effects and Follow-Up to Age Two |
| Q50959104 | Propranolol Treatment of Cavernous Malformations with Symptomatic Hemorrhage. |
| Q49386480 | Propranolol enhanced the anti-tumor effect of sunitinib by inhibiting proliferation and inducing G0/G1/S phase arrest in malignant melanoma. |
| Q89768252 | Propranolol for the Treatment of Lymphatic Malformations in a Neonate - A Case Report and Review of Literature |
| Q40424734 | Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. |
| Q37708790 | Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. |
| Q64931736 | Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway. |
| Q55044813 | Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations. |
| Q36084905 | Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients |
| Q94955381 | Propranolol suppresses the growth of colorectal cancer through simultaneously activating autologous CD8+ T cells and inhibiting tumor AKT/MAPK pathway |
| Q36299241 | Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing. |
| Q61451944 | Propranolol: A 50-Year Historical Perspective |
| Q36278223 | Prospective, open-label, rater-blinded and self-controlled pilot study of the treatment of proliferating superficial infantile hemangiomas with 0.5% topical timolol cream versus 595-nm pulsed dye laser |
| Q41896159 | Psoriasiform Diaper Rash Possibly Induced by Oral Propranolol in an 18-Month-Old Girl with Infantile Hemangioma |
| Q49308699 | Quality of life in children with infantile hemangioma: a case control study |
| Q83230740 | R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma |
| Q41970819 | Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract |
| Q91675732 | Refractive Outcome in Preterm Newborns With ROP After Propranolol Treatment. A Retrospective Observational Cohort Study |
| Q59136527 | Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment |
| Q37404693 | Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent |
| Q28074453 | Repurposing of approved cardiovascular drugs |
| Q40070952 | Role of fine needle aspiration cytology in the differential diagnosis of vascular anomalies from other lesions in the head and neck region |
| Q33577048 | Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience |
| Q33685473 | Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study |
| Q92083673 | Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes |
| Q37130685 | Somatic PIK3CA mutations as a driver of sporadic venous malformations. |
| Q38373964 | Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial. |
| Q51464896 | Subglottic infantile haemangioma: A rare but important consideration in young infants presenting with stridor. |
| Q89727808 | Success in the use of oral propranolol in the treatment of infantile hemangioma in nasal tip - Report of two cases |
| Q33431654 | Successful Propranolol Treatment of a Kaposiform Hemangioendothelioma Apparently Resistant to Propranolol |
| Q52595074 | Successful management of extremely high-output refractory congenital chylothorax with chemical pleurodesis using 4% povidone-iodine and propranolol: a case report. |
| Q36362590 | Temperature Instability in an Infant Treated with Propranolol for Infantile Hemangioma. |
| Q55129507 | The Effect of Oral Propranolol versus Oral Corticosteroids in Management of Pediatric Hemangiomas. |
| Q37321874 | The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. |
| Q38906330 | The changing face of complicated infantile hemangioma treatment |
| Q38691922 | The role of adaptive trial designs in drug development |
| Q91809745 | The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease |
| Q92802002 | Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System |
| Q49932289 | Therapie infantiler Hämangiome |
| Q33835368 | Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma |
| Q60949875 | Topical Timolol Vs. Oral Propranolol for the Treatment of Superficial Infantile Hemangiomas |
| Q38859269 | Transcriptional activation of Hedgehog pathway components in aggressive haemangioma. |
| Q35645474 | Treatment of infantile haemangiomas: recommendations of a European expert group |
| Q38662656 | Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature |
| Q52585802 | Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). |
| Q38380750 | Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls. |
| Q53116834 | Ulcerated infantile haemangiomas: the effect of the selective beta-blocker atenolol on wound healing. |
| Q39215866 | Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol |
| Q38766989 | Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation |
| Q53804973 | Use of propranolol for parotid hemangioma. |
| Q43362685 | Use of propranolol in a remote region of rural Guatemala to treat a large facial infantile haemangioma. |
| Q39447507 | Vascular anomaly cases for the pediatric hematologist oncologists-An interdisciplinary review. |
| Q64098355 | Vascular tumors in infants and adolescents |
| Q41783972 | Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol |
| Q58788212 | Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET |
| Q40824195 | What's new in pediatric dermatology? |
| Q37657969 | When to stop propranolol for infantile hemangioma |
| Q39157785 | Wound management of ulcerated haemangioma of infancy - an audit |
| Q88792083 | [Acute complications of vascular anomalies in childhood] |